# Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

> **NCT00665145** · PHASE2 · COMPLETED · sponsor: **Sangamo Therapeutics** · enrollment: 23 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Polyneuropathy

## Interventions

- **DRUG:** SB-509
- **DRUG:** SB-509
- **DRUG:** Placebo
- **DRUG:** SB-509

## Key facts

- **NCT ID:** NCT00665145
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665145, "Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00665145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*